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role of the upper respiratory tract associated lymphoid tissue, speciﬁcally the nasal associated lymphoid
tissue (NALT), in providing protection has yet to be elucidated. Here we administered Ad85A to BALB/c
mice alone or following BCG priming, using intranasal inocula targeting the whole respiratory tract or
only the NALT, to show that Ad85A induces an immune response in the NALT insufﬁcient to provide
protection. Rather, Ad85A delivered through the respiratory tract must induce a deep lung immune
response in order to protect against M. tuberculosis.
 d85A
. Introduction
Mycobacterium tuberculosis (M.tb) causes 1.7 million deaths
er year [1]. The current vaccine Bacille Calmette Guerin (BCG)
s the most widely used vaccine in the world but has variable
fﬁcacy in children, ranging from 0% to 80%, and poor efﬁcacy in
dults. Thereforebetter vaccines againstM.tb areurgently required,
specially as the frequency of drug-resistant isolates continues to
ise. A range of new generation vaccines are currently in various
tages of clinical development, includingmodiﬁedBCGstrains, pro-
eins, DNA and virally vectored subunit vaccines (reviewed in [2]).
nderstanding themechanismsbywhich these candidatesmediate
rotection will allow them to be used to the greatest effect as well
s aiding more rational design of further generations of vaccines.
Recombinant adenovirus serotype Hu5 expressing antigen 85A
rom M.tb (Ad85A) is one such candidate vaccine and has shown
rotection in mice and guinea pigs when given by the intra-nasal
i.n.) route [3–5]. Administration of the vaccine i.n. generates a
arge population of 85A-speciﬁc CD8+ T-cells in the lung, which
orrelates with protection [3,6–10]. Furthermore, Santosuosso et
l. have shown that the location of the antigen-speciﬁc cells in the
ungs plays an important role in protection [7]. However, there is
ittle information as the role of upper respiratory tract (URT) associ-
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ated lymphoid tissue in protection against M.tb challenge. In mice,
one of the principal lymphoid tissues associated with the URT is
the nasal-associated lymphoid tissue (NALT). The NALT, which is
thought to be an inductive site for immune responses in the URT
[11] is a lymphoid structure at the back of the nasal cavity above
the hard palette, often compared toWaldeyer’s ring in humans, and
has been described as having similar functions to the better studied
gut-associated lymphoid tissue (reviewed in [12,13]). As mice are
obligate nose breathers, the NALT is an important structure as it
is the ﬁrst part of the immune system able to sample inhaled anti-
gen. Although not aswell studied as other similar lymphoid tissues,
it is clear that the NALT plays an important role in the immune
response to some respiratory pathogens, such as reoviruses [11].
However others have shown that removal of the NALT has no effect
on inﬂuenza or pneumococcal infection [14,15] although deple-
tion of CD4 or CD8 T-cells in vivo does increase inﬂuenza virus
titres in the nose after challenge [16]. These data suggest that the
NALT may not be essential for induction of immune responses
to respiratory pathogens but nevertheless antigen-speciﬁc cells
located in the URT may play a role in containment of respiratory
infections. As the NALT would be the ﬁrst structure to encounter
M.tb during aerosol infection we analysed whether it contributes
to protection against M.tb following intra-nasal immunisation
Open access under CC BY-NC-ND license.with a vaccine candidate, Ad85A. By comparing an immunisation
regime that preferentially targets the NALT to one targeting the
whole respiratory tract, we show that only regimes that induce
strong deep lung immune responses protect against aerosol M.tb
challenge.
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number of Ad85A v.p. given in either 6 or 50l induces a compara-
ble number of antigen-speciﬁc CD8+ cells (Fig. 1A and Table 1). In
both groups fewer than 200 antigen-speciﬁc CD8+ T-cells are found
in the NALT (Fig. 1A), although we obtained comparable yields of
cells from the O-NALT to those reported by others for mouse NALT
Table 1
Percentage of antigen-speciﬁc IFN producing CD8+ cells in the NALT and lung after
i.n. immunisation with Ad85A in different volumes. Data presented as the range of
responses seen in at least two experimentswith 4mice per group or as single values
if only one experiment was performed.
NALT CD8+ IFN+ Lung CD8+ IFN+180 E.O. Ronan et al. / Vac
. Materials and methods
.1. Mice
All experiments were performed with 6–8-week-old female
ALB/c mice (Harlan Orlac, Blackthorn, UK), were approved by the
nimal use ethical committee of Oxford University and fully com-
lied with the relevant Home Ofﬁce guidelines.
.2. Immunisation
Human adenovirus serotype 5 expressing antigen 85A was
roduced as described previously [9]. Mice were anaesthetised
ithKetamine/Domitor intra-peritoneally and immunised i.n.with
×109 v.p. of Ad85A suspended in different volumes from 5 to
0l. The mice were allowed to slowly inhale the virus suspen-
ion, half of which was dropped into each nostril. BCG (SSI, kindly
rovided by Dr. Amy Yang, CBER/FDA, MD, USA) was administered
ubcutaneously in the left hind footpad at a dose of 2×105 colony
orming units (CFU) in 30l volume. For i.n. boosting, Ad85A was
iven 10–12 weeks post-BCG.
.3. M. tuberculosis challenge
Mice were challenged by aerosol with M.tb (kindly provided by
r. Amy Yang, Erdman strain, CBER/FDA), using a modiﬁed Hen-
erson apparatus [17] 4 weeks post-Ad85A or 4 months post-BCG
mmunisation. Deposition in the lung was measured 24h post-
hallenge as ∼200CFU of M.tb per mouse. Mice were culled 4–6
eeks post-challenge, lungs and spleen homogenized and 10-fold
ilutions plated onMiddlebrook 7H11 agar plates (E & O Laborato-
ies Ltd., Bonnybridge, UK). Colonies were counted after 3–4weeks
f incubation at 37 ◦C in 5% CO2.
.4. Tissue sampling
The organized NALT (O-NALT) was extracted by removing the
ead from the body, dissecting away the lower jaw, tongue and
onnective tissue to expose the soft palette of the upper jaw. The
ront incisors were then cut away to reveal the anterior end of the
oft palette. Thepalettewas thenpeeledback fromtheanterior end,
ncluding the paired NALT structures at the posterior of the hard
alette. The diffuse NALT (D-NALT) was not removed. The NALT
tructures were disrupted with needles to release the cells, which
ere thenwashed in complete DMEM (10% heat inactivated FBS, l-
lutamine, 2-mercapthoethanol, penicillin and streptomycin). The
ALT cells of all mice in each group were pooled.
LungswereperfusedwithPBS, cut into small pieces anddigested
ith 0.7mg/ml collagenase type I (Sigma, Poole, UK) and 30g/ml
Nase I (Sigma) for 45min at 37 ◦C. Lung fragments were then
rushed through a cell strainer using a 5ml syringe plunger,
ashed, puriﬁed over a cushion of lympholyte (Cederlane, Ontario,
anada), washed again and resuspended in complete DMEM.
.5. Intra-cellular cytokine staining (ICS)
Cells were cultured in complete DMEM and stimulated with
he dominant CD4 (Ag85A99–118aa TFLTSELPGWLQANRHVKPT) and
D8 (Ag85A70–78aa MPVGGQSSF and Ag85A145–152aa YAGAMSGL)
eptide epitopes at 2g/ml. Peptides were synthesized by Peptide
rotein Research Ltd., Fareham, UK. After 1h at 37 ◦C Golgi Plug
BD Biosciences, Oxford, UK) was added according to the manufac-
urer’s instructions and cells were incubated for an additional 5h
efore intracellular cytokine staining. For IL-17 staining Golgi Plug
as added after 2h.8 (2010) 5179–5184
Cellswerewashed and incubatedwithCD16/CD32mAB to block
Fc binding then cells stained for CD4 (RM4-5), CD127 (A7R34),
CD62L (MEL-14), IFN (XMG1.2), IL-2 (JES6-5H4), TNF (MP6-
XT22) and IL-17 (17B7) (eBioscience,Hatﬁeld, UK) andCD8 (53-6.7)
(BD Bioscience) using the BD Cytoﬁx/Cytoperm kit according to
the manufacturer’s instructions. Cells were run on a LSRII (BD
Biosciences) and analysed using FlowJo software (Tree Star, Inc.,
Ashland, OR, USA). The proportions of cells producing different
cytokines were calculated using Spice 5.0, kindly provided by Dr.
M. Roederer, Vaccine Research Centre, NIAID, NIH, USA.
2.6. Statistical tests
All results are representative of at least two independent exper-
iments with similar results. Data were analysed using Student’s
t-test or non-parametric Kruskal–Wallis or Mann–Whitney tests
as indicated in the ﬁgure legends.
3. Results
3.1. Immune responses to Ad85A administered in different
volumes
The volume of an i.n. inoculum has been shown to determine
the location of antibody responses in the respiratory tract, with
smaller volumes eliciting URT responses and larger volumes elicit-
ing responses both in the URT and the deep lung [18]. The particle
size of the antigen or the nature of the aerosol methodology has
also been shown to inﬂuence the localisation of antigen in the res-
piratory tract and the subsequent antibody response [19,20]. It was
therefore important to show that Ad85A administered in small vol-
umes elicited an URT immune response. We therefore immunised
mice with the same number of Ad85A viral particles suspended in
5, 6, 10, 20 or 50l to determine which inocula induced responses
in the NALT and lung. The response was measured as the num-
ber CD8+ T-cells producing IFN- in response to Ad85A peptides
(Table 1). Because delivery of Ad85A in any volumes greater than
6l induced a strong lung response, subsequent experimentswere
carried out using 5–6l to target preferentially the NALT and 50l
to target the whole respiratory tract. Since the kinetics of the NALT
response to adenovirus is not known we also determined the fre-
quency of antigen-speciﬁc IFN- producing cells at different times
after immunisation and found that the maximal response was at
3 weeks (data not shown), comparable to our ﬁndings in the lung
[6,9].
Fig. 1 shows the number of IFN- producing cells in the NALT
and lungs after immunisation with 6 or 50l. ICS was performed
on lung and NALT cells after stimulation with a peptide mix of the
antigen85Adominant CD4 andCD8epitopes. In theNALT, the same5l i.n. 0–0.3% 0%
6l i.n. 0.2–0.6% 0–0.3%
10l i.n. 0.4% 5.7%
20l i.n. 1.2% 13.3%
50l i.n. 0.05–0.5% 2–11%
E.O. Ronan et al. / Vaccine 28 (2010) 5179–5184 5181
Fig. 1. Number of IFN+ cells in lung and NALT. BALB/c mice were immunised i.n.
with 50 or 5–6l of Ad85A. Cells were extracted from the tissues 3 weeks after
Ad85A immunisation. IFN productionwas quantiﬁed by ICS. Bars represent (A) the
total number of CD8+ IFN+ cells per NALT based on the pooled cells from 4 mice
(% IFN+ CD8 cells from pooled mice for 50l is 0.36% and for 5–6l is 0.57%), (B)
total number of CD8+ IFN+ cells per lung for individual mice and the mean (mean
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Fig. 2. Mycobacterial CFU in lung and spleen after M.tb aerosol challenge. BALB/c
mice were immunised with BCG and 10 weeks later immunised i.n. with Ad85A
either in 50 or 5–6l (B-A 50 and B-A5/6). Some mice were given Ad85A only in 50
or 5–6l (A50 andA5/6).Micewere challengedwith∼200CFUofM.tb 4weeks post-
ﬁnal immunisation, culled 4–6 weeks post-M.tb challenge and CFU enumerated for
with different volumes of Ad85AIFN+ CD8 cells for 50l is 1.87% and for 5–6l is 0.31%) and (C) CD4+ IFN+
ells per lung for individual mice and the mean (mean % IFN+ CD4 cells for 50l
s 0.08% and for 5–6l is 0.05%) *p<0.05 as determined by Mann–Whitney test.
epresentative of at least three experiments.
21]. The frequency of responding cells is also low (Table 1), empha-
ising that the response in this site is weak compared to that found
n the lung after i.n. immunisation [6,9]. In contrast, 50l induces
strong CD8+ response in the lung, with a higher frequency and
arge number of antigen-speciﬁc CD8+ T-cells (∼3×104), while a
l inoculum induces fewer than 2000 antigen-speciﬁc CD8+ cells
n the lung (p<0.05) (Fig. 1B). The number of CD4+ antigen-speciﬁc
ells induced in the lungandNALTbya6or50l inoculumofAd85A
as also compared andalthough there appears to be a trend toward
higher response in the lung after administration of 50l, the dif-
erence was not statistically signiﬁcant (Fig. 1C). No CD4+ response
as detectable in the NALT. Thus, immunisation with 6 or 50lnduces a small but comparable CD8+ response in the NALT. How-
ver, although a 6l inoculum induces a very small CD4+ and CD8+
esponse in the lung, a 50l inoculum generates a much stronger
ung CD8+ response.the lungs (A) and spleen (B). The horizontal line represents the median Log CFU per
groupwith each symbol representing onemouse. *p<0.05. Statistical signiﬁcance is
compared to Naive group unless indicated and determined by Kruskal–Wallis test.
Representative of at least three experiments.
3.2. Protection against M.tb challenge after intra-nasal
administration of Ad85A in different volumes
We have previously shown that Ad85A can provide protection
against M.tb challenge when given intra-nasally (i.n.) and that this
protectioncorrelateswith thepresenceof85A-speciﬁcCD8+T-cells
in the lung [6,9,10]. However,we did not assess the role of theNALT
in protection. To investigate this we primed mice with BCG and 10
weeks later boosted with Ad85A i.n. administered in either 5–6l,
to preferentially target the NALT, or 50l to target the whole res-
piratory tract. Further groups of mice received the Ad85A i.n alone
in either 5–6l or 50l (Fig. 2A). After immunisation, mice were
challenged with M.tb by aerosol. Immunisation with Ad85A i.n. in
50l decreasedmycobacterial load in the lung by∼1 log compared
to unimmunised animals when given alone (5.48 log vs. 6.23 log;
p=<0.01) andwhen given as a boost after BCG by∼1 logmore than
BCG (4.49 log vs. 5.47 log; p=<0.01) (Fig. 2A). Immunisation with
Ad85A i.n. in 50l also decreased mycobacterial load in the spleen
by∼1 log compared tounimmunisedcontrols, thoughnoadditional
protection was seen when Ad85A was given as a boost after BCG
(Fig. 2B). However when Ad85Awas administered in 5–6l, either
alone or as a boost after BCG, no effect on mycobacterial load was
detected in lung or spleen (Fig. 2A and B).
3.3. Quality of the immune responses induced by immunisationWe and others have shown previously that protection against
M.tb after Ad85A i.n. immunisation correlates with the presence
of activated CD8+ antigen-speciﬁc cells in the lungs. We therefore
5182 E.O. Ronan et al. / Vaccine 28 (2010) 5179–5184
Table 2
Both the mean number of CD8+ IFN+ cells present per lung within the effector subsets and the percentage of all CD8+ IFN+ cells in each subset. Effector cells are deﬁned
as CD62L− CD127− and effector Memory as CD62L− CD127+. The gating strategy and a FACS plot showing the indicated populations is shown in Ronan et al. [9]. Data are
represented as the mean of 4 mice± SEM. Statistical signiﬁcance was determined by Mann–Whitney test. *p<0.05.
Effector Effector memory
iﬁc cells Total cells % of antigen-speciﬁc cells
675 (±333) * 37.5 (±8.16)
11732 (±2776) 37.8 (±1.14)
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5–6l i.n. 682 (±315)* 47.0 (±3.84) *
50l i.n. 17430 (±4063) 60.9 (±0.98)
xamined the phenotype of antigen-speciﬁc cells in the lungs after
mmunisation with 5–6 or 50l of Ad85A. Antigen-speciﬁc IFN+
D8+ cells were identiﬁed as either effector (CD62L− CD127−),
ffector memory (CD62L− CD127+) or central memory (CD62L+
D127+) phenotype [9,22]. Immunisation with Ad85A in 50l
nduced signiﬁcantly higher numbers of both effector and effector
emory cells than 5–6l and a greater proportion were effector
ells (Table 2). Too few antigen-speciﬁc cells were present in the
ALT after either immunisation to obtain reliable phenotypic data.
We further characterised differences in response to 5–6 or 50l
mmunisationwith Ad85A by determining the number of cells pro-
ucing TNF, IFN and IL-2. ICS was performed on lung cells that
ad been stimulated with the same mix of CD4 and CD8 pep-
ides and the number of cytokine producing cells was determined.
or each of the three cytokines, immunisation with 50l induced
greater response than immunisation with 5–6l (Fig. 3A). As
olyfunctional antigen-speciﬁc T-cells have been reported to be
mportant in protection against several diseases including M.tb
23,24], we assessedwhat proportion of antigen-speciﬁc cells were
ingle (1+), double (2+) or triple (3+) cytokine producers (Fig. 3C).
mmunisation with 50l induces a greater proportion of single
ig. 3. Cytokine production 3 weeks post-Ad85A immunization with 6 or 50l. (A)
he total number of CD8+ cells producing either IFN, IL-2 or TNF per lung± SEM
12 mice/group). **p<0.005; *p<0.05 as determined by Student’s t-test. (B) The
uality of the lung CD8+ response, showing the proportions of cells producing 1, 2
r all 3 of IFN, IL-2 and TNF. Representative of two experiments.
Fig. 4. (A) Total number of lung CD8+ IL-17+ cells induced in individual mice 3
weeks post-Ad85A i.n. immunization (mean % IFN+ CD8 cells for 50l is 0.15% and
for 5–6l is 0.21%) (12 mice/group). *p<0.05 as determined by Student’s t-test. (B)
Representative FACS plots of IL-17 stained CD8 gated lymphocytes stimulated with
85A peptides or from unstimulated controls.
cytokine producing CD8+ T-cells than immunisation with 5–6l
and this difference ismade up of cells producing IFN only (Fig. 3C).
Another cytokine shown to play a role in the immune response
to M.tb is IL-17 [25,26]. ICS was performed on lung cells that had
been stimulated with the mix of CD4 and CD8 peptides and the
frequency of IL-17 producing cells determined. Lungs from mice
immunised with 50l of Ad85A show a signiﬁcantly greater num-
ber of CD8+ IL-17+ cells than those from mice immunised with
5–6l (Fig. 4). There is a trend towards fewer CD4+ IL-17+ cells
in lungs from mice immunised with 6l, however the absolute
number of CD4+IL17+ cells is extremely low, so this data should be
treated with caution (data not shown). IL-17 expression was not
detected in the NALT.
4. Discussion
The role of the URT associated lymphoid tissue in protection
against respiratory infections remains unclear. In a pneumococcal
challengemodel, cauterisation of theNALTdid not affect protection
inducedby intra-nasal vaccination [14]. However, the cauterisation
was performed on infant mice and at this stage NALT development
may not be complete [14]. In a model of inﬂuenza infection, virus-
speciﬁc CD8+ T-cells were shown not to accumulate in the NALT
until after clearance of the infection, indicating that the NALT is not
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he inductive site for an immune response [21]. A similar model of
nﬂuenza challenge showed that ablation of the NALT had no effect
n T-cell recruitment, serumor nasal cavity IgG and IgA levels or on
he speed atwhich the viruswas cleared [15]. However, in contrast,
n intra-nasal model of reovirus infection showed the NALT to be
he inductive site of both humoral and cellular immune responses
11] and in another inﬂuenza virusmodel, depletion of T-cells prior
o virus challenge, increased viral load in both the lungs and nose,
mplying that T-cells restrict viral replication in both sites [16].
It was therefore of interest to assess the role of the NALT in
rotection induced by the viral vectored vaccine candidate Ad85A
gainst another respiratory pathogen, M.tb. We and others have
reviously shown that i.n. immunisationwith Ad85A in 50l gives
rotection againstM.tb challenge comparable to parenteral immu-
isation with BCG (Fig. 2A and B) [4,9]. Here we compared the
rotection afforded by identical numbers of Ad85A v.p. delivered
n 5–6 or 50l i.n. The results show that immunisation in 5–6l
rovides no protection against aerosol challenge with M.tb (Fig. 2),
espite aweak antigen-speciﬁc response in the lung (Fig. 1). Immu-
isation with 5–6l i.n. does however induce a NALT response
omparable to 50l (Fig. 1A). These data indicate that the magni-
udeof the response in the lung, but not in theNALT, correlateswith
rotection. Indeed, a preliminary experiment in which Ad85A was
elivered directly into the trachea (i.t.), thus bypassing the NALT,
ndicated that this regime protected from BCG challenge to a level
omparable to 50l i.n. immunisation.
Assessment of the T-cell phenotypes generated by the 5–6 or
0l inocula showed that the number of CD8+ cells in the lung
roducing IL-2 was greater after immunisation with 50l, as was
he number producing TNF, although the greatest difference was
n the total producing IFN (Fig. 3A). Since it has been suggested
hat the quality of the T-cell response plays an important role in
he response to pathogens such as HIV, malaria and M.tb, with the
roportion of T-cells producing more than one cytokine correlat-
ng with protection [23,24,27,28], we measured the proportions of
ung CD8+ T-cells induced by immunisation with 5–6 or 50l pro-
ucing one, two or all three of IFN, IL-2 and TNF (Fig. 3C). Despite
eing the protective regime, it appears that immunisation with
0l induces more single cytokine producing cells (1+) than with
–6l (Fig. 3C), themain difference being in the number IFN-only
roducing cells (Fig. 3C). Therefore it is likely that a high proportion
f multi-cytokine producing cells is not necessary for protection in
hismodel. Recently theproductionof IL-17bybothCD4+andCD8+
-cells has also been shown to play a role in protection against a
umber of pathogens including M.tb [25,26,29,30]. The same pat-
ern was seen for this cytokine, such that immunisation with 50l
nduced a greater number of antigen-speciﬁc CD8+IL17+ cells in the
ung than immunisation with 5–6l.
The presence in the lung of antigen-speciﬁc CD8+ T-cells of an
ffector phenotype, deﬁned by the level of expression of CD62L
nd CD127 [22], correlates with protection after Ad85A immuni-
ation [9]. Here we show that immunisation with Ad85A in 50l
.n. induces a signiﬁcantly greater number of antigen-speciﬁc effec-
or and effector memory cells in the lung than immunisation in
–6l (Table 2). These phenotypic data indicate that immunisation
ith 50l generates a consistently greater number of antigen-
peciﬁcCD8+T-cells in the lung than5–6l,whether these cells are
etected by production of IFN, IL2, TNF or IL-17, suggesting that
he number of 85A-speciﬁc CD8+ T-cells in the lung at the time of
hallenge is the most important factor determining the extent of
rotection against M.tb.
We suggest that i.n. immunisation with 50l Ad85A has two
mportant effects. The ﬁrst is that antigen delivered to the deep
ung [18] induces an immune response in the draining mediastinal
odes, and the second is that the adenovirus induces inﬂamma-
ion in the lung. This means that antigen-speciﬁc cells leaving the8 (2010) 5179–5184 5183
mediastinal lymph nodes and passing via the thoracic duct, the
right side of the heart and pulmonary arteries, will be recruited
back to the lungs, including the airways, because of local inﬂam-
mation [31]. Any activated, non-antigen-speciﬁc cells in the blood
will most likely also be recruited into the lungs. In contrast, immu-
nisation with a small volume induces a weak immune response in
the NALT and perhaps the cervical nodes, but because the lungs are
not inﬂamed, cells leaving these inductive siteswill notbepreferen-
tially recruited to the lungs. Additionally, because the mechanisms
of homing are partially shared between different mucosal tissues,
it is possible that cells induced in the NALT might return to the
bronchial-associated-lymphoid-tissue (BALT) or to the mucosa of
the large airways of the lung [12]. This may provide another expla-
nation why NALT-induced cells provide little or no protection, as it
is the presence of cells in the airway (bronchioles and alveoli) that
has been correlated with protection [7,8]. Alternatively, since it is
known that mucosal responses are sometimes tolerising, it may be
that in the absence of a mucosal adjuvant the NALT environment
generates non-protective T-cells [32].
The importance of targeting both respiratory and othermucosal
pathogens at their site of entry is becoming more apparent. With
the development of more vaccines that can be delivered to the res-
piratory tract [33], it is vital to understand the role of different
parts of the airway in providing protection as well as the con-
sequences of different modes of delivery. Here we have shown
that delivering the Ad85A vaccine to the URT associated NALT is
not enough to protect against aerosol M.tb challenge in BALB/c
mice. A possible factor in the failure of small volume i.n. immu-
nisation to protect against M.tb challenge, apart from the lack of
homing of large numbers of immune cells to the lungs, may be the
weak immune response generated in the NALT by Ad85A. This is
a problem that has been encountered with other i.n. vaccine can-
didates and a variety of adjuvants have been tested in attempts to
improve URT immune responses [34]. However, these may have
side effects such as facial nerve palsy [35]. Inappropriate immu-
nisation can also lead to worsening of lung pathology, as in the
case of the formalin inactivated respiratory syncytial virus vaccine
tested in the 1960s [36]. Deep lung immunisationwith Ad85A gen-
erates a long-lived highly activated lung T cell population, raising
the possibility of exacerbation of disease following infection with
respiratory pathogens or in asthma.
In contrast to the difﬁculty in inducing a strong immune
response in the URT with Ad85A, administration of the same
vaccine to the deep lung does not require an adjuvant to gen-
erate a large resident antigen-speciﬁc CD8+ population. Deep
lung immunisation with Ad85A provides partial protection against
M.tb when given alone and additive protection when used as
a booster after BCG. These ﬁndings have implications for the
design of vaccines against M.tb to be delivered by the respiratory
tract.
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